Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of IMM-101 plus radiation-induced tumour necrosis in previously treated metastatic colorectal cancer
2011-003958-85Phase 2Completed
- Sponsor
- Immodulon Therapeutics
- Start
- Dec 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IMM-101 in metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC), sponsored by Immodulon Therapeutics. Primary endpoint: Disease stabilisation rate at 24 weeks. Started Dec 2011; status: completed.
02
Drugs
IMM-101
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2011-003958-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003958-85.